Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zolmitriptan
Drug ID BADD_D02393
Description Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan.[A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment.[A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997. It is currently available in both tablet and nasal spray forms.[L12978]
Indications and Usage Zolmitriptan is indicated for the acute treatment of migraine with or without auras in patients aged 18 and over.[L12978]
Marketing Status approved; investigational
ATC Code N02CC03
DrugBank ID DB00315
KEGG ID D00415
MeSH ID C089750
PubChem ID 60857
TTD Drug ID D0NG7O
NDC Product Code 64567-0016; 63548-0101; 64896-681; 64896-682; 64980-256; 68001-250; 72189-435; 65372-1145; 16571-803; 69238-2007; 65977-0050; 67835-5007; 64896-692; 65841-765; 65841-766; 64896-691; 64980-204; 69097-864; 71626-101; 72189-434; 65015-688; 46708-182; 64896-672; 68001-249; 68462-498; 60846-2384; 64896-671; 64980-203; 64980-257; 65841-768; 68382-715; 68462-497; 69097-863; 63548-0102; 63629-9575; 68382-712; 72606-567; 54864-955; 27241-022; 68382-717; 68462-499; 11722-012; 63850-4322; 45802-711; 46708-181; 46708-463; 55700-943; 55700-944; 68382-714; 69238-2006; 55111-800; 27241-021; 46708-462; 60846-2383; 65841-767; 65862-914; 65862-915; 68462-500; 71626-102; 72606-568; 65862-801; 66039-845; 16571-804
UNII 2FS66TH3YW
Synonyms zolmitriptan | 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone | Zomig | AscoTop | Zomigoro | 311C90 | Flezol
Chemical Information
Molecular Formula C16H21N3O2
CAS Registry Number 139264-17-8
SMILES CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Feeling abnormal08.01.09.0140.003453%Not Available
Feeling cold08.01.09.008--Not Available
Feeling hot08.01.09.009--Not Available
Flat affect19.04.01.004--Not Available
Gastritis07.08.02.001--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal carcinoma16.13.04.001; 07.21.03.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Gingivitis07.09.10.002; 11.01.04.013--
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Hair disorder23.02.06.003--Not Available
Hallucination19.10.04.003--
Headache17.14.01.0010.010764%
Hemianopia17.17.01.012; 06.02.07.0040.001692%Not Available
Hemiparesis17.01.04.0010.002031%
Hepatic neoplasm16.07.03.001; 09.04.03.001--Not Available
Hepatocellular injury09.01.07.0080.000677%Not Available
Hiccups22.12.01.001; 07.01.06.009--
Hyperacusis17.04.03.003; 04.02.02.001--Not Available
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.0280.002031%
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hyperthyroidism14.11.01.011; 05.02.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperventilation19.01.02.004; 22.02.01.006--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 10 Pages